Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2006.
Note to Editors
TYKERB(R) is a registered trademark of the GlaxoSmithKline group of companies in the United States.
TYVERB(R) is a registered trademark of the GlaxoSmithKline group of companies in Europe and is the proposed trade name in certain markets, pending regulatory approval.
Herceptin(R) is a registered trademark of Genentech, Inc. in the U.S. and Roche Pharmaceuticals in Europe.
Xeloda(R) is a registered trademark of Roche Pharmaceuticals.
To access the latest GSK Oncology media materials, visit http://www.gsk.com/media.
US Media enquiries: Sarah Alspach +1 919 483 2839
Mary Anne Rhyne +1 919 483 2839
UK Media enquiries: Philip Thomson +44 20 8047 5502
Claire Brough +44 20 8047 5502
Joss Mathieson +44 20 8047 5502
Alice Hunt +44 20 8047 5502
European Analyst/Investor enquiries:
David Mawdsley +44 20 8047 5564
Sally Ferguson +44 20 8047 5543
US Analyst/ Investor enquiries:
Copyright©2007 PR Newswire.
All rights reserved